OOIR: Observatory of International Research

Papers

(The TQCC of Molecular Neurodegeneration is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Retraction Note: Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5– implications for dementia with lewy bodies	445
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	252
Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer’s disease through disrupted regulated intramembrane proteolysis	242
Molecular hallmarks of excitatory and inhibitory neuronal resilience to Alzheimer’s disease	236
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	232
LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome	220
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	209
Tau interactome and RNA binding proteins in neurodegenerative diseases	198
Regulation of the hippocampal translatome by Apoer2-ICD release	191
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	177
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	169
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	150
Microglia sensing of peripheral signals that bridge the brain and body	149
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	136
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model	116
Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer’s disease genetic pathways	112
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	106
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	98
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	97
Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases	95
Recombinant cathepsins B and L promote α-synuclein clearance and restore lysosomal function in human and murine models with α-synuclein pathology	94
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	94
Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement	92
The role of NURR1 in metabolic abnormalities of Parkinson’s disease	91
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition	91

Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	89
Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	89
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	82
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	79
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	79
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps	77
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	77
In Memoriam of Edward H. Koo, MD 1954–2025	77
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	75
Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	75
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	73
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	73
Autophagic impairment in sleep–wake circuitry is linked to sleep loss at the early stages of Alzheimer’s disease	66
Entering the era of precision medicine to treat amyotrophic lateral sclerosis	65
Combination therapy using GDNF and cell transplant in Parkinson’s disease	65
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	62
Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease	61
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease	59
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	59
Correction: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	58
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses	57
Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor degeneration during chronic HIF activation	57
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics	57
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function	56
Correction: HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	55
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	53
Using mass spectrometry to validate mouse models of tauopathy	53
Dementia with lewy bodies patients with high tau levels display unique proteome profiles	53
Methylome analysis of FTLD patients with TDP-43 pathology identifies epigenetic signatures specific to pathological subtypes	52
Evidence suggesting that microglia make amyloid from neuronally expressed APP: a hypothesis	52
Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer’s disease	52
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis	51
The endotoxin hypothesis of Alzheimer’s disease	49
RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD	48
The transcription factor combination MEF2 and KLF7 promotes axonal sprouting in the injured spinal cord with functional improvement and regeneration-associated gene expression	48
The PKCι-β-arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer’s disease	48
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease	47
Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease	46
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration	45
Glial phagocytosis for synapse and toxic proteins in neurodegenerative diseases	44
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	44
APOE genotype influences on the brain metabolome of aging mice – role for mitochondrial energetics in mechanisms of resilience in APOE2 genotype	44
The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer’s disease	44
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	44
The Hippo signaling pathway as a therapeutic target in Alzheimer’s disease	43
Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	43
Cerebrospinal fluid proteome profiling across the Alzheimer’s disease continuum: a step towards solving the equation for ‘X’	43
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis	42
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	42
Sex specific molecular networks and key drivers of Alzheimer’s disease	40

VCP suppresses proteopathic seeding in neurons	40
Interplay between astrocyte reactivity and APOE ε4 status is associated with accelerated pTau-related tau pathology in Alzheimer’s disease	40
Mechanisms of astrocyte aging in reactivity and disease	40
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice	39
Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans	39
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	39
NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	38
Correction: Blood–brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	38
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer’s disease	38
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	37
Current strategies in the management of dementia with lewy bodies and future directions based on disease pathophysiology	37
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP	37
Neuropathology and molecular diagnosis of Synucleinopathies	37
Correction: Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	36
Nuclear pore and nucleocytoplasmic transport impairment in oxidative stress-induced neurodegeneration: relevance to molecular mechanisms in Pathogenesis of Parkinson’s and other related neurodegenerat	36
Increased expression of mesencephalic astrocyte-derived neurotrophic factor (MANF) contributes to synapse loss in Alzheimer’s disease	35
CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice	35
Therapeutic potential of APP antisense oligonucleotides for Alzheimer’s disease and down syndrome-related Alzheimer’s disease	35
Modulation of O-GlcNAc cycling influences α-synuclein amplification, degradation, and associated neuroinflammatory pathology	34
MicroRNA-100-5p and microRNA-298-5p released from apoptotic cortical neurons are endogenous Toll-like receptor 7/8 ligands that contribute to neurodegeneration	34
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience	34
Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology	33
The role of inflammasomes in vascular cognitive impairment	32
Pathological characteristics of axons and alterations of proteomic and lipidomic profiles in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency	32
Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies	32
Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	32
Proteomic landscape of Alzheimer’s disease: emerging technologies, advances and insights (2021 – 2025)	32
Correction: Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model	32
Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature	31
Blood platelet factor 4: the elixir of brain rejuvenation	31
Age-dependent progression from clearance to vulnerability in the early response of periventricular microglia to α-synuclein toxic species	31